- [TERAPIA GÉNICA Y REGULACIÓN DE LA EXPRESIÓN GÉNICA]
- [TERAPIA GÉNICA PARA CÁNCER]
- [TERAPIA GÉNICA DE ENFERMEDADES CONGÉNITAS CON AFECTACIÓN NEUROLÓGICA]
- [INMUNOLOGÍA E INMUNOTERAPIA]
- [INMUNOMODULACIÓN Y MICROAMBIENTE TUMORAL]
- [ESTRATEGIAS COMBINADAS DE INMUNOTERAPIA TRASLACIONAL]
- [TERAPIA CELULAR ADOPTIVA]
Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses
Maria Cristina Ballesteros-Briones, Eva Martisova, Erkuden Casales, Noelia Silva-Pilipich, Maria Buñuales, Javier Galindo, Uxua Mancheño, Marta Gorraiz, Juan J Lasarte, Grazyna Kochan, David Escors, Alfonso R Sanchez-Paulete, Ignacio Melero, Jesus Prieto, Ruben Hernandez-Alcoceba, Sandra Hervas-Stubbs, Cristian Smerdou
Immune checkpoint blockade has shown anti-cancer efficacy, but requires systemic administration of monoclonal antibodies (mAbs), often leading to adverse effects. To avoid toxicity, mAbs could be expressed locally in tumors. We developed adeno-associated virus (AAV) and Semliki Forest virus (SFV) vectors expressing anti-programmed death ligand 1 (aPDL1) mAb.
When injected intratumorally in MC38 tumors, both viral vectors led to similar local mAb expression at 24 h, diminishing quickly in SFV-aPDL1-treated tumors. However, SFV-aPDL1 induced >40% complete regressions and was superior to AAV-aPDL1, as well as to aPDL1 mAb given systemically or locally. SFV-aPDL1 induced abscopal effects and was also efficacious against B16-ovalbumin (OVA). The higher SFV-aPDL1 antitumor activity could be related to local upregulation of interferon-stimulated genes because of SFV RNA replication.
This was confirmed by combining local SFV-LacZ administration and systemic aPDL1 mAb, which provided higher antitumor effects than each separated agent. SFV-aPDL1 promoted tumor-specific CD8 T cells infiltration in both tumor models. In MC38, SFV-aPDL1 upregulated co-stimulatory markers (CD137/OX40) in tumor CD8 T cells, and its combination with anti-CD137 mAb showed more pronounced antitumor effects than each single agent. These results indicate that local transient expression of immunomodulatory mAbs using non-propagative RNA vectors inducing type I interferon (IFN-I) responses represents a potent and safe approach for cancer treatment.
CITA DEL ARTÍCULO Mol Ther. 2019 Nov 6;27(11):1892-1905. doi: 10.1016/j.ymthe.2019.09.016. Epub 2019 Sep 16.